Document is current
Any future updates will be listed below
-
Authors
Xu-Monette, Zijun Y.
Li, Jianyong
Xia, Yi
Crossley, Beryl
Bremel, Robert D.
Miao, Yi
Xiao, Min
Snyder, Thomas
Manyam, Ganiraju C.
Tan, Xiaohong
Zhang, Hongwei
Visco, Carlo
Tzankov, Alexandar
Dybkaer, Karen
Bhagat, Govind
Tam, Wayne
You, Hua
Hsi, Eric D.
van Krieken, J. Han
Huh, Jooryung
Ponzoni, Maurilio
Ferreri, Andrés J. M.
Møller, Michael B.
Piris, Miguel A.
Winter, Jane N.
Medeiros, Jeffrey T.
Xu, Bing
Li, Yong
Kirsch, Ilan
Young, Ken H.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA233490)
National Cancer institute (R01CA138688)
National Cancer Institute (1RC1CA146299)
National Cancer Institute (R01CA187415)
- License Information
-
More Information
Article History
Received: 19 December 2018
Accepted: 4 September 2019
First Online: 22 October 2019
Ethics approval and consent to participate
: The study was conducted in accordance with the Declaration of Helsinki as part of the International DLBCL Rituximab-CHOP Consortium Program. Data collection protocols were approved as being of minimal to no risk or as exempt by the institutional review board of each participating institution.
: Not applicable.
: B.C. and I.K. are employees of Adaptive Biotechnologies. R.D.B. is a co-founder of ioGenetics LLC. T.S. is a former employee of Adaptive Biotechnologies. K.H.Y. receives research support from Adaptive Biotechnologies, Roche Molecular Diagnostics, Gilead Sciences, Seattle Genetics, Daiichi Sankyo, Incyte Corporation, and HTG Molecular Diagnostics. Other authors declare no conflicts of interest.
